Hemogenyx Pharmaceuticals (HEMO) Competitors GBX 144.23 +2.23 (+1.57%) As of 08/8/2025 10:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock HEMO vs. AOR, SAR, RLM, FAB, POLB, NSCI, IXI, APTA, OPTI, and OBDShould you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include AorTech International (AOR), Sareum (SAR), Realm Therapeutics (RLM), Fusion Antibodies (FAB), Poolbeg Pharma (POLB), NetScientific (NSCI), IXICO (IXI), Aptamer Group (APTA), OptiBiotix Health (OPTI), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry. Hemogenyx Pharmaceuticals vs. Its Competitors AorTech International Sareum Realm Therapeutics Fusion Antibodies Poolbeg Pharma NetScientific IXICO Aptamer Group OptiBiotix Health Oxford BioDynamics Hemogenyx Pharmaceuticals (LON:HEMO) and AorTech International (LON:AOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Is HEMO or AOR more profitable? AorTech International's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Hemogenyx PharmaceuticalsN/A -80.66% -37.79% AorTech International N/A N/A N/A Which has stronger earnings & valuation, HEMO or AOR? AorTech International has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than AorTech International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHemogenyx PharmaceuticalsN/AN/A-£6.89K-£0.20-737.81AorTech International£539K0.00N/A-£3.70N/A Does the media favor HEMO or AOR? In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled AorTech International'saverage media sentiment score. Company Overall Sentiment Hemogenyx Pharmaceuticals Neutral AorTech International Neutral Do institutionals and insiders have more ownership in HEMO or AOR? 0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryAorTech International beats Hemogenyx Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Hemogenyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEMO vs. The Competition Export to ExcelMetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£5.14M£137.45M£5.52B£3.07BDividend YieldN/A3.74%4.60%5.03%P/E Ratio-737.813.7830.01170.60Price / SalesN/A4,424.80450.05303,757.13Price / Cash2.0513.1936.7727.96Price / Book585.4539.278.184.52Net Income-£6.89K-£90.99M£3.26B£5.90B7 Day Performance-7.83%2.15%6.13%1.23%1 Month Performance-1.18%3.15%0.07%3.22%1 Year Performance11,221.04%183.58%36.31%60.28% Hemogenyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEMOHemogenyx PharmaceuticalsN/AGBX 144.23+1.6%N/A+11,229.9%£5.14MN/A-737.8114Gap UpAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383SARSareumN/AGBX 16-3.0%N/A-45.4%£19.99MN/A-3.793,211Gap UpRLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501.92K-0.66N/AFABFusion AntibodiesN/AGBX 14flatN/A+354.5%£13.17M£2.09M-3.1548News CoveragePositive NewsGap UpHigh Trading VolumePOLBPoolbeg PharmaN/AGBX 2.53-0.7%N/A-78.4%£13.02MN/A0.0012NSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626IXIIXICON/AGBX 12.25+2.1%N/A+63.3%£11.35M£11.50M-3.1789Gap UpAPTAAptamer GroupN/AGBX 0.56+10.5%N/A+106.7%£11.09M£4.12M-0.7837Gap UpHigh Trading VolumeOPTIOptiBiotix HealthN/AGBX 10.50-2.3%N/A-61.1%£10.28M£590.01K-3.321OBDOxford BioDynamicsN/AGBX 0.48-3.4%N/A-93.1%£9.11M£5.75M-0.0845 Related Companies and Tools Related Companies AorTech International Alternatives Sareum Alternatives Realm Therapeutics Alternatives Fusion Antibodies Alternatives Poolbeg Pharma Alternatives NetScientific Alternatives IXICO Alternatives Aptamer Group Alternatives OptiBiotix Health Alternatives Oxford BioDynamics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:HEMO) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEMO Stock Alerts